This website is intended for U.S. Healthcare Professionals.
REVLIMID is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib. REVLIMID is not indicated and is not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.
Findings of the MCL clinical trial.
Efficacy and safety of REVLIMID were evaluated in the relapsed or refractory MCL clinical trial.1
See Clinical Trial Results
Once-daily oral dosing.1†
Learn more about the REVLIMID dosing schedule.
Learn More†Days 1-21 of a 28-day cycle
Your resources.
Download useful tools and access a list of helpful organizations for your patients.
See ResourcesCLL, chronic lymphocytic leukemia.